非清髓异基因造血干细胞移植治疗2例恶性血液病长期生存并自然生育的病例分析  

Non-myeloablative allogeneic hematopoietic stem cell transplantation for the treatment of 2 patients with hematological malignancies with long term survival and natural birth

作　　者：刘娟 吕攀攀 黄晓梅 曲媛媛 杨亚坤 孙万军 LIU Juan;LYU Panpan;HUANG Xiaomei;QU Yuanyuan;YANG Yakun;SUN Wanjun(Department of Hematology,Chinese PLA Rocket Force Characteristic Medical Center,Beijing 100088,China)

机构地区：[1]中国人民解放军火箭军特色医学中心血液科,北京100088

出　　处：《现代肿瘤医学》2023年第11期2102-2104,共3页Journal of Modern Oncology

基　　金：首都卫生发展科研专项自主创新基金(编号:2022-2-5111)。

摘　　要：目的:探讨非清髓异基因造血干细胞移植(non-myeloablative allogeneic hematopoietic stem cell transplantation,NMA allo-HSCT)对恶性血液病的疗效和生育功能的影响。方法:报道2例恶性血液病患者经NMA allo-HSCT治疗的过程及生育情况,并复习相关文献。结果:1例为25岁MDS转化的AML女性患者,1例为32岁NHL女性患者,均接受NMA allo-HSCT,截至随访日期(2022-10-01),2例患者分别无病生存190个月和115个月,且均自然生育健康子女。结论:NMA allo-HSCT治疗恶性血液病患者取得了长期生存,并保留了生育功能。Objective:To explore the efficacy and fertility of non-myeloablative(NMA)allogeneic hematopoietic stem cell transplantation(allo-HSCT)for hematologic malignancies.Methods:The process and fertility of 2 patients with hematologic malignancies treated with NMA allo-HSCT were reported,and the related literatures were reviewed.Results:One 25-year-old female patient with acute myeloid leukemia(AML)transformed from myelodysplastic syndrome(MDS)and one 32-year-old female patient with non Hodgkin's lymphoma(NHL)received NMA allo-HSCT treatment.Up to the follow-up date(2022-10-01),2 patients had diseases free survival with 190 months and 115 months,respectively,and both had naturally given birth to healthy children.Conclusion:NMA allo-HSCT benefited hematologic malignancies with long-term survival and preserved fertility.

关 键 词：异基因造血干细胞移植 非清髓方案 长期生存 生育 

分 类 号：R733.3[医药卫生—肿瘤]